[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoproliferative-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoproliferative-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,230,270,299,322,345],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100305619","phase-2-nivolumab-in-epstein-barr-virus-ebv-positive-lymphoproliferative-disorders-and-ebv-positive-non-hodgkinlymphomas-100305619",false,"NCT03258567","Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas","Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas","* INCLUSION CRITERIA:\n* Subjects must have histologically or cytologically confirmed EBV-positive LPD or an EBV-positive NHL confirmed by the Laboratory of Pathology, NCI.\n\n  * EBV-positive LPD. Subjects may be previously untreated or relapsed from prior therapy.\n\n    1. Lymphomatoid granulomatosis (LYG), grades I-II\n    2. Chronic active EBV disease (CAEBV) of B-cells or T-cells\n    3. EBV-positive post-transplantation lymphoproliferative disorder (PTLD)\n\n       NOTE: PTLD after solid organ transplantation is excluded. Patients who, at the discretion of the investigator, need urgent therapy with standard agents will not be eligible.\n  * EBV-positive B-cell NHL. Subjects must have relapsed from previous treatment with an anthracycline and rituximab-based regimen or be considered not eligible for the same.\n\n    1. Lymphomatoid granulomatosis (LYG), grade III\n    2. EBV-positive immunodeficiency-associated diffuse large B-cell lymphoma (DLBCL)\n    3. EBV-positive DLBCL\n* Subjects must be at least 2 weeks from prior anti-lymphoma therapy (including radiation therapy)\n* Subjects must be at least 100 days from prior stem cell transplant (autologous or allogeneic) or Donor Lymphocyte Infusion (DLI)\n\n  * Age \\>=12 years\n  * Patients \\>= 12 and \\\u003C 18 years of age should weigh at least 40 kilograms (kg); there is no weight requirement for adult subjects.\n  * NOTE: If a pediatric patient is identified for possible enrollment who weighs less than 40 kg, the safety of the nivolumab dosing strategy used in this study must be discussed with the PI and manufacturer to confirm safety, and this discussion\u002Fapproval for enrollment documented in the medical record prior to declaring the pediatric patient eligible.\n* Adequate performance status as follows:\n\n  * Patients \\>= 16 years must have ECOG Performance Status 0-2 (Karnofsky \\>=60%)\n  * Pediatric patients \\\u003C 16 years must have Lansky play-performance of 60-100%\n* Subjects must have measurable or evaluable disease.\n* Subjects must have adequate organ and bone marrow reserve (unless disease-related) as defined below:\n\n  * absolute neutrophil count - \\>= 750\u002FmcL; \\>= 500\u002FmcL if impairment is due to LPD\u002FNHL\n  * platelets - \\>= 50,000\u002FmcL; \\>= 25,000\u002FmcL if impairment is due to LPD\u002FNHL (transfusions not permitted)\n  * Hemoglobin - \\>= 9g\u002FdL (transfusion permitted)\n  * total bilirubin - \\\u003C 3.0g\u002Fdl OR \\\u003C 5.0g\u002Fdl if Gilbert s syndrome or disease infiltration of the liver is present\n  * AST(SGOT)\u002FALT(SGPT) - \\\u003C= 3 X institutional upper limit of normal\n  * serum creatinine OR creatinine clearance - Adults: \\\u003C= 1.5 mg\u002FdL; Minors: serum Cr \\\u003C= age-adjusted normal OR \\>= 40 ml\u002Fmin\u002F1.73m\\^2\n\nAge(Years) 12-15: Maximum Serum Creatinine (mg\u002Fdl): 1.2\n\nAge(Years) \\> 15: Maximum Serum Creatinine (mg\u002Fdl): 1.5\n\n* A formalin fixed tissue block or at least 15 slides of tumor sample (archival or fresh) must be available for performance of correlative studies. NOTE: Patient must be willing to have a pre-treatment tumor biopsy if adequate archival tissue is not available.\n* The toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknown. For this reason, we will introduce early stopping rules.\n* The effects of nivolumab on the developing human fetus are unknown. For this reason, the following measures apply:\n\n  * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) during screening and within 48 hours prior to the first dose of nivolumab.\n  * WOCBP and men who are sexually active with WOCBP must use adequate contraception (e.g., hormonal or 2 barrier methods with a failure rate of less than 1% per year or abstinence) prior to study entry and throughout study drug administration. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product.\n  * Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception).\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), and who is not postmenopausal. Post menopause is defined as:\n\n    1. Amenorrhea \\>= 12 consecutive months without another cause, and a documented serum follicle stimulating hormone (FSH) level \\> 35 mIU\u002FmL or\n    2. Women with irregular menstrual periods and a documented serum follicle stimulating hormone (FSH) level \\> 35 mIU\u002FmL or NOTE: FSH level testing is not required for women \\>= 62 years old with amenorrhea of \\>= 1 year\n    3. Women on hormone replacement therapy (HRT)\n* Pregnant women are excluded from this study because nivolumab is an IgG monoclonal antibody with the potential for teratogenic or abortifacient effects.\n* Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab, nursing should be discontinued if the mother is treated with nivolumab.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and sign the written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Subjects who are receiving any other investigational agents.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab.\n* Subjects with second malignancies requiring active systemic therapy are excluded. Subjects with second malignancies not requiring active systemic therapy or pre-malignant conditions such as monoclonal B-cell lymphocytosis (MBL) or monoclonal gammopathy of undetermined significance (MGUS) may be eligible.\n* Subjects with any condition or autoimmune disease that requires systemic corticosteroids (\\> 10 mg daily prednisone equivalents) or immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids are permitted.\n* Subjects with active graft-vs-host disease (GVHD) requiring steroids or other immunosuppressive agents; history of \\>=grade II acute GVHD or extensive chronic GVHD.\n* Subjects who have had solid organ transplant.\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody.\n* Non-oncology vaccine therapies for prevention of infectious disease within 4 weeks of study drug administration.\n* A serious uncontrolled medical condition requiring therapy.\n* Seizures disorder not controlled by anti-seizure medications.\n* Subjects with CNS involvement may be included on the study as long as they have not had any seizure activity in past 4 weeks.\n* Hepatitis B virus surface antigen positive.\n* Active Hepatitis C infection with a positive PCR; subjects who are Hepatitis C antibody positive and PCR negative may be eligible. In these cases, the subjects will be monitored via HCV PCR throughout the study.\n* History of anaphylactic reaction to monoclonal antibody therapy.\n* HIV positive subjects are excluded because the function of their T-cell immune responses is impaired.","ALL","12 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Background:\n\nThe drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments.\n\nObjectives:\n\nTo see if Nivolumab slows the growth of some types of cancer or stops them from getting worse. To test the safety of the drug.\n\nEligibility:\n\nPeople 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders or EBV-positive non-Hodgkin lymphomas with no standard therapy\n\nDesign:\n\nParticipants will be screened with:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests\n\nCAT scan of the chest, abdomen, and pelvis\n\nTumor and bone marrow biopsies (sample taken)\n\nMagnetic resonance imaging scan of the brain\n\nLumbar puncture (also known as spinal tap)\n\nPositron emission tomography\u002Fcomputed tomography scan with a radioactive tracer\n\nEvery 2 weeks, participants will get Nivolumab by vein over about 1 hour. They will also have:\n\nPhysical exam\n\nBlood and pregnancy tests\n\nReview of side effects and medications\n\nDuring the study, participants will repeat most of the screening tests. They may also have other biopsies.\n\nAfter stopping treatment, participants will have a visit every 3 months for 1 year. Then they will have a visit every 6 months for years 2-5, and then once a year. They will have a physical exam and blood tests.\n\n...",[26,27,28,29],"Epstein-Barr Virus Infections","Lymphoma","Lymphoproliferative Disorder","Disorders, Lymphoproliferative",[31],"Monoclonal Antibody","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2018-04-26",{"date":40,"type":20},"2031-06-01",{"name":42,"class":43},"National Cancer Institute (NCI)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":5},"100143410","registry-of-older-patients-with-cancer-100143410","NCT01137825","Registry of Older Patients With Cancer","Carolina Senior: UNC Registry for Older Cancer Patients","DISEASE CHARACTERISTICS:\n\n* Patients must have an appointment at the North Carolina Cancer Hospital and agree to complete the Geriatric Assessment NOTE: Not all patients included in the registry will ultimately be diagnosed with cancer. Patients who complete a GA and are not diagnosed with cancer will remain in the database, but will be categorized into a separate group and will not have their medical records accessed.\n\nPATIENT CHARACTERISTICS:\n\n* Able to read and speak English\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","65 Years",{"count":54,"type":20},3000,"OBSERVATIONAL","RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future.\n\nPURPOSE: This research study is gathering information from older patients with cancer into a registry.",[58,59,60,27,28,61,62,63,64],"Chronic Myeloproliferative Disorders","Cognitive\u002FFunctional Effects","Leukemia","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unspecified Adult Solid Tumor, Protocol Specific",[66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219],"cognitive\u002Ffunctional effects","unspecified adult solid tumor, protocol specific","accelerated phase chronic myelogenous leukemia","acute undifferentiated leukemia","adult acute lymphoblastic leukemia in remission","adult acute myeloid leukemia in remission","adult acute myeloid leukemia with 11q23 (MLL) abnormalities","adult acute myeloid leukemia with inv(16)(p13;q22)","adult acute myeloid leukemia with t(15;17)(q22;q12)","adult acute myeloid leukemia with t(16;16)(p13;q22)","adult acute myeloid leukemia with t(8;21)(q22;q22)","atypical chronic myeloid leukemia, BCR-ABL negative","blastic phase chronic myelogenous leukemia","chronic myelomonocytic leukemia","chronic phase chronic myelogenous leukemia","mast cell leukemia","meningeal chronic myelogenous leukemia","progressive hairy cell leukemia, initial treatment","prolymphocytic leukemia","recurrent adult acute lymphoblastic leukemia","recurrent adult acute myeloid leukemia","recurrent adult T-cell leukemia\u002Flymphoma","refractory chronic lymphocytic leukemia","refractory hairy cell leukemia","relapsing chronic myelogenous leukemia","secondary acute myeloid leukemia","stage 0 chronic lymphocytic leukemia","stage I adult T-cell leukemia\u002Flymphoma","stage I chronic lymphocytic leukemia","stage II adult T-cell leukemia\u002Flymphoma","stage II chronic lymphocytic leukemia","stage III adult T-cell leukemia\u002Flymphoma","stage III chronic lymphocytic leukemia","stage IV adult T-cell leukemia\u002Flymphoma","stage IV chronic lymphocytic leukemia","T-cell large granular lymphocyte leukemia","untreated adult acute lymphoblastic leukemia","untreated adult acute myeloid leukemia","untreated hairy cell leukemia","recurrent adult Hodgkin lymphoma","stage I adult Hodgkin lymphoma","stage II adult Hodgkin lymphoma","stage III adult Hodgkin lymphoma","stage IV adult Hodgkin lymphoma","anaplastic large cell lymphoma","angioimmunoblastic T-cell lymphoma","cutaneous B-cell non-Hodgkin lymphoma","recurrent cutaneous T-cell non-Hodgkin lymphoma","stage I cutaneous T-cell non-Hodgkin lymphoma","stage II cutaneous T-cell non-Hodgkin lymphoma","stage III cutaneous T-cell non-Hodgkin lymphoma","stage IV cutaneous T-cell non-Hodgkin lymphoma","recurrent mycosis fungoides\u002FSezary syndrome","stage I mycosis fungoides\u002FSezary syndrome","stage II mycosis fungoides\u002FSezary syndrome","stage III mycosis fungoides\u002FSezary syndrome","stage IV mycosis fungoides\u002FSezary syndrome","adult grade III lymphomatoid granulomatosis","adult nasal type extranodal NK\u002FT-cell lymphoma","Waldenstrom macroglobulinemia","extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","nodal marginal zone B-cell lymphoma","splenic marginal zone lymphoma","contiguous stage II adult Burkitt lymphoma","contiguous stage II adult diffuse large cell lymphoma","contiguous stage II adult diffuse mixed cell lymphoma","contiguous stage II adult diffuse small cleaved cell lymphoma","contiguous stage II adult immunoblastic large cell lymphoma","contiguous stage II adult lymphoblastic lymphoma","contiguous stage II grade 1 follicular lymphoma","contiguous stage II grade 2 follicular lymphoma","contiguous stage II grade 3 follicular lymphoma","contiguous stage II mantle cell lymphoma","contiguous stage II marginal zone lymphoma","contiguous stage II small lymphocytic lymphoma","stage I adult Burkitt lymphoma","stage I adult diffuse large cell lymphoma","stage I adult diffuse mixed cell lymphoma","stage I adult diffuse small cleaved cell lymphoma","stage I adult immunoblastic large cell lymphoma","stage I adult lymphoblastic lymphoma","stage I grade 1 follicular lymphoma","stage I grade 2 follicular lymphoma","stage I grade 3 follicular lymphoma","stage I mantle cell lymphoma","stage I marginal zone lymphoma","stage I small lymphocytic lymphoma","noncontiguous stage II adult Burkitt lymphoma","noncontiguous stage II adult diffuse large cell lymphoma","noncontiguous stage II adult diffuse mixed cell lymphoma","noncontiguous stage II adult diffuse small cleaved cell lymphoma","noncontiguous stage II adult immunoblastic large cell lymphoma","noncontiguous stage II adult lymphoblastic lymphoma","noncontiguous stage II grade 1 follicular lymphoma","noncontiguous stage II grade 2 follicular lymphoma","noncontiguous stage II grade 3 follicular lymphoma","noncontiguous stage II mantle cell lymphoma","noncontiguous stage II marginal zone lymphoma","noncontiguous stage II small lymphocytic lymphoma","stage III adult Burkitt lymphoma","stage III adult diffuse large cell lymphoma","stage III adult diffuse mixed cell lymphoma","stage III adult diffuse small cleaved cell lymphoma","stage III adult immunoblastic large cell lymphoma","stage III adult lymphoblastic lymphoma","stage III grade 1 follicular lymphoma","stage III grade 2 follicular lymphoma","stage III grade 3 follicular lymphoma","stage III mantle cell lymphoma","stage III marginal zone lymphoma","stage III small lymphocytic lymphoma","stage IV adult Burkitt lymphoma","stage IV adult diffuse large cell lymphoma","stage IV adult diffuse mixed cell lymphoma","stage IV adult diffuse small cleaved cell lymphoma","stage IV adult immunoblastic large cell lymphoma","stage IV adult lymphoblastic lymphoma","stage IV grade 1 follicular lymphoma","stage IV grade 2 follicular lymphoma","stage IV grade 3 follicular lymphoma","stage IV mantle cell lymphoma","stage IV marginal zone lymphoma","stage IV small lymphocytic lymphoma","recurrent adult Burkitt lymphoma","recurrent adult diffuse large cell lymphoma","recurrent adult diffuse mixed cell lymphoma","recurrent adult diffuse small cleaved cell lymphoma","recurrent adult grade III lymphomatoid granulomatosis","recurrent adult immunoblastic large cell lymphoma","recurrent adult lymphoblastic lymphoma","recurrent grade 1 follicular lymphoma","recurrent grade 2 follicular lymphoma","recurrent grade 3 follicular lymphoma","recurrent mantle cell lymphoma","recurrent marginal zone lymphoma","recurrent small lymphocytic lymphoma","intraocular lymphoma","post-transplant lymphoproliferative disorder","chronic eosinophilic leukemia","chronic neutrophilic leukemia","primary myelofibrosis","essential thrombocythemia","polycythemia vera","extramedullary plasmacytoma","isolated plasmacytoma of bone","stage I multiple myeloma","stage II multiple myeloma","stage III multiple myeloma","primary systemic amyloidosis","refractory multiple myeloma","de novo myelodysplastic syndromes","previously treated myelodysplastic syndromes","secondary myelodysplastic syndromes","myelodysplastic\u002Fmyeloproliferative neoplasm, unclassifiable","2026-06-24",{"date":222,"type":36},"2026-06-29",{"date":224,"type":4},"2009-09",{"date":226,"type":20},"2030-12",{"name":228,"class":229},"UNC Lineberger Comprehensive Cancer Center","OTHER",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":269},"100239986","project-every-child-for-younger-patients-with-cancer-100239986","NCT02402244","Project: Every Child for Younger Patients With Cancer","The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study","Inclusion Criteria:\n\n* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem\n* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority\n* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:\n\n  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one \"1\" (borderline), two \"2\" (carcinoma in situ) or three \"3\" (malignant)\n  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant\n  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant\n  * The following other benign\u002Fborderline conditions:\n\n    * Mesoblastic nephroma\n    * Teratomas (mature and immature types)\n    * Myeloproliferative diseases including transient myeloproliferative disease\n    * Langerhans cell histiocytosis\n    * Lymphoproliferative diseases\n    * Desmoid tumors\n    * Gonadal stromal cell tumors\n    * Neuroendocrine tumors including pheochromocytoma\n    * Melanocytic tumors, except clearly benign nevi\n    * Ganglioneuromas\n* Subjects must be =\\\u003C 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \\[NCTN\\]) therapeutic study, for which there is a higher upper age limit\n* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission\n\n  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1","25 Years",{"count":239,"type":20},75000,"This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.",[242,243,244,245,246,247,248,249,250,251,28,252,253,254,255,256,257,258],"Adrenal Gland Pheochromocytoma","Carcinoma In Situ","Central Nervous System Neoplasm","Childhood Immature Teratoma","Childhood Kidney Neoplasm","Childhood Langerhans Cell Histiocytosis","Childhood Mature Teratoma","Congenital Mesoblastic Nephroma","Desmoid Fibromatosis","Ganglioneuroma","Malignant Neoplasm","Malignant Solid Neoplasm","Melanocytic Neoplasm","Myeloproliferative Neoplasm","Neoplasm of Uncertain Malignant Potential","Neuroendocrine Neoplasm","Stromal Neoplasm","2026-05-01",{"date":261,"type":36},"2026-05-05",{"date":263,"type":36},"2015-11-03",{"date":265,"type":20},"2030-12-31",{"name":267,"class":268},"Children's Oncology Group","NETWORK",278,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":44},"100430312","phase-2-acalabrutinib-and-obinutuzumab-for-the-treatment-of-previously-untreated-follicular-lymphoma-or-other-indolent-non-hodgkin-lymphomas-100430312","NCT04883437","Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients With Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas","Inclusion Criteria:\n\n* Men and women \\>= 18 years of age\n* Patients will need to have one of the following clinical scenarios:\n\n  * Previously untreated follicular lymphoma grade 1-3a with low tumor burden by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria\n  * Previously untreated follicular lymphoma grade 1-3a with high tumor burden by GELF criteria but who are unable or unwilling to receive standard front-line treatment approaches\n  * Previously untreated marginal zone lymphoma, lymphoplasmacytic lymphoma, or any other indolent B-cell lymphoproliferative disorder with low tumor burden by GELF criteria or who are unable\u002Funwilling to receive more intensive front-line treatment\n  * Previously untreated mantle cell lymphoma who would otherwise be appropriate candidates for watchful waiting OR who have symptomatic disease but are not candidates for or decline standard induction approaches\n* Patients with previously untreated low tumor burden FL (criterion above) must have measurable and\u002For assessable disease defined as at least one involved lymph node or extranodal disease site that measures \\>= 1.5cm in greatest diameter\n* Patients who meet inclusion criteria above are eligible as long as they meet one of the following criteria for measurable\u002Fassessable disease:\n\n  * At least one involved lymph node or extranodal disease site measuring \\> 1.5cm in greatest diameter\n  * Pathologically-confirmed bone marrow or peripheral blood involvement that can be reassessed for response\n  * Pathologically confirmed splenic or extranodal involvement with at least one known site of disease remaining after diagnostic biopsy that can be reassessed (i.e., patients with splenic marginal zone lymphoma who complete splenectomy and have no other detectable disease would not be eligible)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Woman of childbearing potential (WOCBP) and men enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation, and for at least 2 days after the last dose of acalabrutinib or 18 months after the last dose of obinutuzumab, whichever is longer. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Women of childbearing potential must have a negative serum or urine pregnancy test prior to starting therapy\n* Willing and able to participate in all required evaluations and procedures in this study protocol\n* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information\n\nExclusion Criteria:\n\n* The presence or history of histologically transformed or co-existing high-grade or aggressive non-Hodgkin lymphoma\n* Confirmed active or prior central nervous system disease\n* Prior receipt of lymphoma-directed therapy or prior antibody-based therapy (except for anti-microbial therapy for infection-associated marginal zone lymphoma such as hepatitis C or H pylori)\n\n  * A short course of steroids is permitted for patients aside from those in the low tumor burden FL cohort. This course may be no more than 14 days and steroids must be discontinued (or tapered to =\\\u003C 10mg prednisone or equivalent) no later than 3 days after initiation of study treatment. Patients in the low tumor burden FL cohort may not receive corticosteroids as an anti-lymphoma therapy at any time before starting treatment\n* Prior malignancy (or any other malignancy requiring active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for \\>= 2 years or which will not limit survival to \\\u003C 5 years\n* Clinically significant cardiovascular disease such as symptomatic ventricular arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. Note: Subjects with controlled, asymptomatic atrial fibrillation can enroll on study if deemed appropriate by the investigator\n* Has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease that would limit absorption of oral medication\n* Known history of human immunodeficiency (HIV) or any active significant infection (e.g., bacterial, viral, or fungal) within 14 days of cycle 1. Patients with uncomplicated viral or bacterial infections that are being managed with oral antibiotics and\u002For supportive care alone are eligible\n* Known history of hypersensitivity or anaphylaxis to study drug(s) including active product or excipient components\n* Active bleeding or history of bleeding diathesis (e.g., hemophilia or von Willebrand disease)\n* Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)\n* Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening\n* Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor\u002Finducer\n* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists\n* Requires treatment with proton pump inhibitors (e.g, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Note: Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study\n* History of significant cerebrovascular disease\u002Fevent, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug. Patients with a transient ischemic attack which has resolved and for which there are no ongoing symptoms are eligible\n* Major surgical procedure within 28 days of first dose of study drug (not including a diagnostic procedure to make the lymphoma diagnosis). Note: If a subject had major surgery, they must have recovered adequately from any toxicity and\u002For complications from the intervention before the first dose of study drug\n* Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antigen (HBsAg) negative will need to have a negative polymerase chain reaction (PCR) and must be willing to undergo deoxyribonucleic acid (DNA) PCR testing during the study to be eligible. Those who are HBsAg positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result to be eligible and have completed appropriate anti-viral treatment. Those who are hepatitis C PCR positive will be excluded. Anti-viral therapy for patients with hepatitis-C associated marginal zone lymphoma will not be considered a prior anti-lymphoma treatment\n* Absolute neutrophil count (ANC) \\\u003C 1,000\u002FmcL\n* Platelet count \\\u003C 50,000\u002FmcL (Unless felt to be related to underlying disease)\n* Total bilirubin \\>= 1.5 x the upper limit of normal (ULN). Isolated bilirubin \\> 1.5 x ULN is permitted if the direct proportion is \\\u003C 35%\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) \\> 2.5 x ULN\n* Creatinine clearance =\\\u003C 40 mL\u002Fmin\u002F1.73m\\^2\n* Breastfeeding or pregnant\n* Concurrent participation in another therapeutic clinical trial","18 Years",{"count":279,"type":20},49,[23],"This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.",[283,284,285,286,287,28,288,289],"Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Indolent Non-Hodgkin Lymphoma","Lymphoplasmacytic Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","2026-02-05",{"date":292,"type":36},"2026-02-09",{"date":294,"type":36},"2021-09-03",{"date":296,"type":20},"2027-01-15",{"name":298,"class":229},"Emory University",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":5},"100564509","understanding-the-mechanisms-of-clonal-and-non-clonal-cytopenia-following-car-t-therapy-for-multiple-myeloma-or-cd19-lymphoproliferative-disorder-lpd-100564509","NCT06630104","Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)","MC230818 Understanding the Mechanisms of Clonal and Non-Clonal Cytopenia Following CAR-T Therapy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically or cytologically confirmed diagnosis of multiple myeloma (MM) as defined in International Myeloma Working Group (IMWG) criteria or a CD19+ lymphoproliferative disorder (LPD) as defined by 2016 World Health Organization (WHO) classification\n* Provide written informed consent\n* Willingness to provide mandatory bone marrow aspirate specimens for correlative research. All bone marrow aspirate samples are collected during a clinical procedure\n* Willingness to provide mandatory hair follicle specimens for correlative research\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Willingness to provide saliva and buccal samples for research\n\nExclusion Criteria:\n\n* Ineligible for CAR-T therapy\n* Patients diagnosed with myeloid neoplasm before CAR-T therapy",{"count":307,"type":20},82,[309],"NA","This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric antigen receptor T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients experience cytopenia that last longer than 30 days post-infusion. Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic\u002Fgenomic testing is a series of tests that find specific changes in cancer cells or in blood deoxyribonucleic acid. Identifying gene mutations may help identify the risk of cytopenia in patients with multiple myeloma or CD19 positive LPD following CAR-T therapy.",[28,312],"Multiple Myeloma","2026-01-06",{"date":315,"type":36},"2026-01-08",{"date":317,"type":36},"2024-11-22",{"date":319,"type":20},"2027-12-16",{"name":321,"class":229},"Mayo Clinic",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":44},"100143396","tissue-blood-and-body-fluid-sample-collection-from-patients-with-hematologic-cancer-100143396","NCT01137643","Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer","Tissue Procurement For Hematolymphoid Conditions","DISEASE CHARACTERISTICS:\n\n* Diagnosis of abnormal hematopoietic\u002Flymphoid cancer, including any of the following:\n\n  * Acute myeloid leukemia\n  * Acute lymphoblastic leukemia\n  * Chronic myelogenous leukemia\n  * Chronic lymphoid leukemia\n  * Non-Hodgkin lymphoma\n  * Hodgkin lymphoma\n  * Myelodysplastic syndromes\n  * Myeloproliferative disorders\n  * Multiple myeloma\n  * Waldenstrom macroglobulinemia\n  * Aplastic anemia\n  * Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage\n* Patients who are being evaluated at the hematology\u002Foncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","120 Years",{"count":331,"type":20},15000,"RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.\n\nPURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.",[58,60,27,28,61,62,63,334],"Nonmalignant Neoplasm",[68,69,70,71,72,73,74,75,76,77,78,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,336],"aplastic anemia","2025-10-23",{"date":339,"type":36},"2025-10-27",{"date":341,"type":4},"2009-07",{"date":343,"type":20},"2040-07",{"name":228,"class":229},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":277,"maxAge":329,"enrollmentInfo":4,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":364,"locationsCount":44},"100128032","3-deoxy-3-18f-fluorothymidine-pet-imaging-in-patients-with-cancer-100128032","NCT00935090","3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer","Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)","DISEASE CHARACTERISTICS:\n\n* Meets one of the following criteria:\n\n  * Histologically confirmed solid tumor or hematologic malignancy\n  * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging\n\nPATIENT CHARACTERISTICS:\n\n* Able to lie still in the PET scanner\n* Girth and weight must be suitable to enter the gantry\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\\[18F\\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.\n\nPURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.",[354,58,60,27,28,61,62,63,64],"Brain and Central Nervous System Tumors",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,356,357,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219],"primary central nervous system non-Hodgkin lymphoma","primary central nervous system Hodgkin lymphoma","2025-07-02",{"date":360,"type":36},"2025-07-08",{"date":224,"type":36},{"date":363,"type":20},"2028-05",{"name":365,"class":229},"Barbara Ann Karmanos Cancer Institute"]